• How big of a difference is a patient likely to detect [5] ? • Have we overlooked women as we design laboratory and clinical research studies [7] ? • And what is the difference between efficacy and safety [6] ?
By comparison, the question of durability may have gotten short shrift. For decades now, our specialty-and our Journal-have relied on the nowubiquitous Kaplan-Meier method of estimating survivorship [4] . This approach is superior to crude survivorship calculations since the Kaplan-Meier estimator adjusts for patients whose status cannot be determined because they have not failed as of the end of the study, or because they have been lost to followup. Two generations (or more) of orthopaedic surgeons have grown accustomed to using the familiar-looking survivorship curves we find in intermediate-and long-term followup papers about our reconstructions. That just about covers it, right?
Maybe not. The Kaplan-Meier approach is extremely effective for the purpose for which it was designed: Estimating survival, defined as the absence of death. In orthopaedic surgery, however, survivorship often refers to the absence of failure of a reconstruction. And here, the KaplanMeier method has shortcomings, particularly if some of the patients who underwent surgical reconstruction die at some point during a study's followup period. Imagine a paper on the durability of a particular arthroplasty design that followed patients for more than a decade. A large proportion of patients will enjoy continued use of the implant for the full study period and beyond, some will undergo revision surgery, others will be lost to followup (and so might get revised, but we do not know), and still others may die from causes unrelated to the reconstruction. Well-functioning and revised implants each represent obvious endpoints for analysis, and Kaplan-Meier statistics adjust the survivorship estimates to account for those others who are lost and may have been revised. But while a patient who is lost to followup may undergo revision, a patient who has died cannot. The presence of such competing events-defined as outcomes (such as death) that preclude the occurrence of the endpoint of interest (revision)-are not accounted for in Kaplan-Meier estimates.
In technical terms, the event of death is informative-a dead patient cannot later develop an implant failure. But Kaplan-Meier survivorship treats those lost to followup (and who may subsequently undergo revision) similarly to those who have died (and so cannot undergo revision). Because of this, the Kaplan-Meier approach will overestimate the likelihood of implant failure if a substantial proportion of a study's patients have died [1, 2, 8] .
Better approaches exist for this scenario [1, 2, 8] . Competing-risk calculations (sometimes called competing-incidence analyses) take into account the combined probability of a patient experiencing implant failure (the event of interest) given that (s)he has survived thus far, without implant failure or death (the competing risk). If a substantial proportion of patients die during the followup period, then late failure becomes less likely, and the survivorship estimate is increased accordingly. Since death precludes a later implant failure, the competingrisk model accounts for the fact that we know that an individual has no chance of needing revision surgery after death.
The differences between KaplanMeier survivorship and a competingrisks estimate can be large [9] , and some of the world's arthroplasty registries have begun to acknowledge this by employing a competing-risks approach in lieu of Kaplan-Meier statistics where appropriate [3] . But the differences are not always large. When is the issue of competing risk small enough to not matter? Imagine another hypothetical study, in which a population of 100 patients have undergone tumor surgery for limb salvage. During the period of followup, one patient underwent amputation following a motor vehicle accident. While amputation in this scenario indeed precludes tumor recurrence, it was a rare event, and the competing risk therefore was very low. Therefore, in that scenario, KaplanMeier survivorship would be a suitable analytical approach to use.
In those situations where the frequency of the competing event is greater than 10% to 20%, and the followup duration starts to approach 10 years (Fig. 1A-F) , Clinical Orthopaedics and Related Research 1 will begin asking authors to consider alternatives to Kaplan-Meier survivorship, such as a competing-risks analysis. Where those alternatives cannot be implemented, we will ask authors to address this issue thoughtfully in the discussion section as an important study limitation.
And we encourage readers to consider this issue carefully when reading studies where survivorship is an important outcome measure.
